Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells.
Neurol Ther
; 12(6): 2041-2052, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37715885
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Neurol Ther
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: